Korsana Biosciences, Inc. (KRSA)
Snapshot
- 1 week
- -3.3%-2.9% vs SPY
- 1 month
- -3.1%-2.0% vs SPY
- Market cap
- $146.6M
- P/E
- negindustry 15.0
- P/B
- 3.7
- EV/EBITDA
- -21.6
- FCF yield
- -3.0%
- Short % float
- 0.7%
- Days to cover
- 1.0
- Short change
- +160.1%
- Consensus
- Buy2 buy · 0 hold · 0 sell
- Price target
- $53.00+69.3% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Korsana Biosciences, Inc. (KRSA). Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
- Regina GraulChief Executive Officer, President & DirectorUSD 572K
- Rhonda ChickoChief Financial OfficerUSD 355K
Snapshot
Price & returns1 month -3.1%
- 1 week
- -3.3%-2.9% vs SPY
- 1 month
- -3.1%-2.0% vs SPY
ValuationP/E neg vs industry 15.0 · market cap $146.6M
- Market cap
- $146.6M
- P/E
- negindustry 15.0
- P/B
- 3.7
- EV/EBITDA
- -21.6
- FCF yield
- -3.0%
Short interest & optionsshort 0.7% of float
- Short % float
- 0.7%
- Days to cover
- 1.0
- Short change
- +160.1%
Street & earningsTarget $53.00 (+69.3% upside)2 buy · 0 hold · 0 sell
- Consensus
- Buy2 buy · 0 hold · 0 sell
- Price target
- $53.00+69.3% upside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Korsana Biosciences, Inc. (KRSA). Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
- Regina GraulChief Executive Officer, President & DirectorUSD 572K
- Rhonda ChickoChief Financial OfficerUSD 355K
